This week in biotech news, Oryon Cell Therapies announced promising data from its Phase Ib/IIa study on a neuron replacement therapy for Parkinson’s disease, supported by a total of $42 million in funding. Additionally, Siren Biotechnology received FDA clearance for its IND application for a gene therapy targeting recurrent high-grade glioma, allowing for a Phase I safety study. Gilead Sciences also moved to acquire Ouro Medicines, enhancing its portfolio with a bispecific T-cell engager aimed at immune-mediated diseases.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.regmednet.com/cell-therapy-weekly-biotech-emerges-from-stealth-with-parkinsons-disease-program/
